Lambert-Eaton Myasthenic Syndrome Market By Treatment (Potassium Channel Blockers (Amifampridine), Cholinesterase Inhibitor (Pyridostigmine), Immune Therapy, Intravenous Immunoglobulin, Plasmapheresis) - Growth, Future Prospects And Competitive Landscape, 2019 – 2027
Industry Outlook
The Lambert-Eaton Myasthenic Syndrome (LEMS) market is keen to represent linear growth at a compounded annual growth rate (CAGR) of 6.7% during the forecast period from 2019 to 2027. LEMS is a rare autoimmune disorder which is manifested by the clinical triad which comprises of reduced tendon reflexes, autonomic symptoms and proximal muscle weakness. Most of the patients suffering with LEMS go undiagnosed at an early age due to its overlapping symptoms similar to small cell lung cancer (SCLC).
"Recent FDA approval of amifampridine for treating LEMS in children and fast track & orphan drug designation to incentivize its growth during the forecast period"
Currently there is no permanent cure for the treatment of LEMS disease in children, the medicine prescribed by physicians worldwide are to attenuate the clinical manifestations related to LEMS disease. Depending on the identification of the symptoms occurring in the adult population the drugs prescribed for its treatment are potassium channel blockers, cholinesterase inhibitor, immune therapy, intravenous immunoglobulin, Plasmapheresis etc. USFDA has recently approved amifampridine for the treatment of LEMS in children from 6 to 17 years of age. It has received orphan drug and fast track designation status which will proactively incentivize the drug development for curing rare diseases.
"Significant rise in clinical research to cure orphan diseases and domicile of major players together drive the market growth in North America region"
North America is currently dominating the regional segment for Lambert-Eaton Myasthenic syndrome (LEMS) market holding 39% share. The major factors responsible for its positive growth profile are significant rise in clinical research activities to cure orphan diseases. According to the Center for Disease Control and Prevention (CDC), research findings approximately 3% of the patients suffering with small cell lung cancer (SCLC) are suffering with Lambert-Eaton Myasthenic syndrome (LEMS). The prevalence rate of SCLC in the United States is 5 cases per million population. Domicile of major players such as Biomarin Pharmaceutical, Inc., Catalyst, Pharmaceuticals, Inc., Merck & Co., Inc. etc. propel the market growth in North America region. Europe holds the second position representing a market share of 34.5% owing to the high incidence rate of LEMS in the European community. As per the research citing of European LEMS Registry the incidence rate is 0.48 to 0.75 per million people, the low prevalence rate I comparison to the incidence rate is due to the poor survival of LEMS patient with paraneoplastic type of disease. Asia Pacific is currently holding 14% market share primarily due to large patient population suffering with SCLC and proactive government initiatives in providing financial aid for the treatment of rare diseases.
Historical & Forecast Period
This research report presents the analysis of each segment from 2017 to 2027 considering 2018 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2019 to 2027.
Report Scope by Segments
The market is segmented by treatment and by geography.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2017-2027 |
| Base Year | 2018 |
| Forecast Period | 2019-2027 |
| Historical Year | 2017 |
| Unit | USD Million |
| Segmentation |
By Treatment (2017–2027; US$ Mn) |
|
Geography Segment (2017–2027; US$ Mn) |
Pharmaceutical manufacturers providing medications for the treatment of Lambert-Eaton Myasthenic Syndrome are Allergan, Plc., Biomarin Pharmaceutical, Inc., Catalyst Pharmaceuticals, Inc., F. Hoffman-La Roche Ltd., GlaxoSmithkline, Plc., Jacobus Pharmaceutical Company, Inc., Kawasumi Laboratories, Inc., Merck & Co., Inc., Mitsubishi Pharma Corporation.
Key questions answered in this report
- Which pharmaceutical companies are engaged in the treatment of LEMS?
- What is the global prevalence rate of LEMS and clinical manifestation overlapping with cancer?
- Brief explanation of DRO’s associated with LEMS market?
- Which drug received the USFDA orphan drug and fast track designation for the treatment of LEMS in children?
- What is the incidence rate in developed countries such as Europe and North America?
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Treatment
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global LEMS Market Portraiture
2.2. Global LEMS Market, by Treatment, 2018 (US$ Mn)
2.3. Global LEMS Market, by Geography, 2018 (US$ Mn)
Chapter 3. Lambert-Eaton Myasthenic Syndrome (LEMS) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global LEMS Market, by Key Players, 2018
Chapter 4. Global Lambert-Eaton Myasthenic Syndrome (LEMS) Market, by Treatment
4.1. Overview
4.2. Potassium Channel Blockers (Amifampridine)
4.3. Cholinesterase Inhibitor (Pyridostigmine)
4.4. Immune Therapy
4.5. Intravenous Immunoglobulin
4.6. Plasmapheresis
Chapter 5. Global Lambert-Eaton Myasthenic Syndrome (LEMS) Market, by Geography
5.1. Overview
5.2. North America LEMS Market Analysis, 2017 – 2027
5.2.1. North America LEMS Market, by Treatment, 2017 – 2027 (US$ Mn)
5.2.2. North America LEMS Market, by Country, 2017 – 2027 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe LEMS Market Analysis, 2017– 2027
5.3.1. Europe LEMS Market, by Treatment, 2017 – 2027 (US$ Mn)
5.3.2. Europe LEMS Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific LEMS Market Analysis, 2017 – 2027
5.4.1. Asia Pacific LEMS Market, by Treatment, 2017 – 2027 (US$ Mn)
5.4.2. Asia Pacific LEMS Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America LEMS Market Analysis, 2017 – 2027
5.5.1. Latin America LEMS Market, by Treatment, 2017 – 2027 (US$ Mn)
5.5.2. Latin America LEMS Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa LEMS Market Analysis, 2017 – 2027
5.6.1. MEA LEMS Market, by Treatment, 2017 – 2027 (US$ Mn)
5.6.2. MEA LEMS Market, by Region, 2017– 2027 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA
Chapter 6. Company Profiles
6.1. Allergan, Plc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Biomarin Pharmaceutical, Inc.
6.3. Catalyst Pharmaceuticals, Inc.
6.4. F. Hoffman-La Roche Ltd.
6.5. GlaxoSmithkline, Plc.
6.6. Jacobus Pharmaceutical Company, Inc.
6.7. Kawasumi Laboratories, Inc.
6.8. Merck & Co., Inc.
6.9. Mitsubishi Pharma Corporation
6.10. Novartis AG
* Here we are using LEMS as a short form of Lambert-Eaton Myasthenic Syndrome
TABLE 1 Global Lambert-Eaton Myasthenic Syndrome (LEMS) Market Portraiture
TABLE 2 Global LEMS Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 3 Global LEMS Market, by Geography, 2017 – 2027 (US$ Mn)
TABLE 4 North America LEMS Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 5 North America LEMS Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 6 Europe LEMS Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 7 Europe LEMS Market, by Country/Region, 2017– 2027 (US$ Mn)
TABLE 8 Asia Pacific LEMS Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 9 Asia Pacific LEMS Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 Latin America LEMS Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 11 Latin America LEMS Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 12 Middle East and Africa LEMS Market, by Treatment, 2017– 2027 (US$ Mn)
TABLE 13 Middle East and Africa LEMS Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 14 Allergan, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 Biomarin Pharmaceutical, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 Catalyst Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 F. Hoffman-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 GlaxoSmithkline, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Jacobus Pharmaceutical Company, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Kawasumi Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Mitsubishi Pharma Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
FIG. 1 Lambert-Eaton Myasthenic Syndrome (LEMS) Market: Research Methodology
FIG. 2 LEMS: Market Segmentation
FIG. 3 Global LEMS Market, by Treatment, 2018 (US$ Mn)
FIG. 4 Global LEMS Market, by Geography, 2018 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2018
FIG. 6 Competitive Analysis: Global LEMS Market, by Key Players, 2018
FIG. 7 Global Potassium Channel Blockers Market for LEMS, 2017 – 2027 (US$ Mn)
FIG. 8 Global Cholinesterase Inhibitor Market for LEMS, 2017 – 2027 (US$ Mn)
FIG. 9 Global Immune Therapy Market for LEMS, 2017 – 2027 (US$ Mn)
FIG. 10 Global Intravenous Immunoglobulin Market for LEMS, 2017– 2027 (US$ Mn)
FIG. 11 Global Plasmapheresis Market for LEMS, 2017 – 2027 (US$ Mn)
FIG. 12 U.S. LEMS Market, 2017 – 2027 (US$ Mn)
FIG. 13 Canada LEMS Market, 2017 – 2027 (US$ Mn)
FIG. 14 U.K. LEMS Market, 2017 – 2027 (US$ Mn)
FIG. 15 Germany LEMS Market, 2017 – 2027 (US$ Mn)
FIG. 16 Rest of Europe LEMS Market, 2017 – 2027 (US$ Mn)
FIG. 17 China LEMS Market, 2017– 2027 (US$ Mn)
FIG. 18 Japan LEMS Market, 2017 – 2027 (US$ Mn)
FIG. 19 Rest of Asia Pacific LEMS Market, 2017 – 2027 (US$ Mn)
FIG. 20 Brazil LEMS Market, 2017 – 2027 (US$ Mn)
FIG. 21 Mexico LEMS Market, 2017 – 2027 (US$ Mn)
FIG. 22 Rest of Latin America LEMS Market, 2017 – 2027 (US$ Mn)
FIG. 23 GCC LEMS Market, 2017 – 2027 (US$ Mn)
FIG. 24 Rest of Middle East and Africa LEMS Market, 2017 – 2027 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)